🧠 Immune Cells in Rare Brain Disease Found 'Exhausted' in New Study

Key Findings

Researchers discovered that microglia—the brain's immune cells—appear "dozy or exhausted" in patients with multiple system atrophy (MSA), a finding that challenges expectations of an overactive immune response.

A new study from the University of Copenhagen and Bispebjerg and Frederiksberg Hospital analyzed brain tissue from patients with MSA, a rare and fatal neurodegenerative disease.

Using single-cell RNA sequencing, scientists examined over 117,000 cells from the striatum of seven MSA patients, 12 Parkinson's disease patients, and ten healthy controls.

The study found that microglia were less active in MSA patients compared to Parkinson's patients, particularly in later disease stages.

"We expected a very active immune system but found the opposite—microglia appear dozy or exhausted." — Konstantin Khodosevich, professor at BRIC

The 'Exhaustion' Hypothesis

Researchers theorize that microglia may become exhausted after initial overactivation, potentially allowing the disease to progress unchecked.

"We have a theory that overactivation may exhaust immune cells, allowing disease to develop more easily." — Susana Aznar, research leader at Bispebjerg and Frederiksberg Hospital

This hypothesis could explain why MSA—a disease affecting movement, balance, and autonomic functions—progresses faster than Parkinson's disease.

Study Limitations

The researchers caution that their findings do not establish causation. The study is also limited by the small number of MSA samples available for analysis.

"We analyzed individual cell nuclei to see what happens at the end of the disease process." — Rasmus Rydbirk, first author

The Bigger Picture

MSA currently has no cure or treatment. The role of microglia in this devastating disease was previously unclear.

"It's important to research MSA to find treatments or a cure." — Inge Vium, chairperson of the Danish MSA association

Looking Ahead

The findings suggest microglia may be a potential target for future MSA treatments, but researchers emphasize that further research is needed before any clinical applications can be developed.